Novartis to trial own drugs with BMS's PD-1
This article was originally published in Scrip
Executive Summary
Novartis is to explore the treatment of lung cancer using a combination of Bristol-Myers Squibb's cancer immune therapy Opdivo (nivolumab) with some of its own molecular targeting agents.